This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TCR2 Therapeutics Dividend
Dividend criteriumcontroles 0/6
TCR2 Therapeutics does not have a record of paying a dividend.
Belangrijke informatie
n/a
Dividendrendement
n/a
Uitbetalingsratio
| Gemiddelde opbrengst industrie | 1.9% |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Winst per aandeel | -US$4.15 |
| Dividendrendementsvoorspelling | n/a |
Recente dividendupdates
Geen updates
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Insufficient data to determine if TCRR's dividends per share have been stable in the past.
Groeiend dividend: Insufficient data to determine if TCRR's dividend payments have been increasing.
Dividendrendement versus markt
| TCR2 Therapeutics Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (TCRR) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.4% |
| Gemiddelde industrie (Biotechs) | 1.9% |
| Analist prognose (TCRR) (tot 3 jaar) | n/a |
Opmerkelijk dividend: Unable to evaluate TCRR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hoog dividend: Unable to evaluate TCRR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Winstuitkering aan aandeelhouders
Verdiendekking: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: Unable to calculate sustainability of dividends as TCRR has not reported any payouts.